KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Inventory: 2017-2024

Historic Inventory for Ionis Pharmaceuticals (IONS) over the last 8 years, with Dec 2024 value amounting to $12.5 million.

  • Ionis Pharmaceuticals' Inventory fell 63.20% to $10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year decrease of 63.20%. This contributed to the annual value of $12.5 million for FY2024, which is 68.15% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Inventory of $12.5 million as of FY2024, which was up 68.15% from $7.4 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Inventory high stood at $24.8 million for FY2021, and its period low was $7.4 million during FY2023.
  • For the 3-year period, Ionis Pharmaceuticals' Inventory averaged around $14.0 million, with its median value being $12.5 million (2024).
  • Its Inventory has fluctuated over the past 5 years, first plummeted by 66.23% in 2023, then soared by 68.15% in 2024.
  • Ionis Pharmaceuticals' Inventory (Yearly) stood at $22.0 million in 2020, then increased by 12.93% to $24.8 million in 2021, then fell by 11.18% to $22.0 million in 2022, then crashed by 66.23% to $7.4 million in 2023, then spiked by 68.15% to $12.5 million in 2024.